NFKB1 and non-small cell lung carcinoma: Hence, we assumed that NF-κB increased the level of miR-21, which reduced PTEN expression post-transcriptionally to promote cell survival under cisplatin treatment in NSCLC; therefore, inhibition of the NF-κB/miR-21/PTEN pathway might be a potential drug target for NSCLC.